期刊文献+

酸性环境抑制CIK细胞对肝癌HepG2细胞的杀伤活性 被引量:1

Inhibition Effect of Acid Environment on Cytotoxicity of Cytokine-induced Killer Cells Against Hepatocellular Carcinoma Cells HepG2
下载PDF
导出
摘要 目的研究酸性环境对CIK(cytokine-induced killer,CIK)细胞杀伤肝癌HepG2细胞的影响。方法利用IFN-γ、IL-2及CD3抗体诱导外周血单个核细胞获得CIK细胞。在pH6.5及pH7.4条件下将CIK细胞和荧光素酶标记的HepG2细胞(HepG2-luc)按不同的效靶比混合培养,用小动物活体成像系统检测HepG2-luc荧光强度并计算杀伤活性,用MTT法检测并计算杀伤活性。在pH6.5及pH7.4条件下,在含CIK条件培养液0、50%和100%的情况下培养HepG2细胞,流式细胞仪检测凋亡坏死的细胞比例。结果 pH7.4时CIK细胞对HepG2细胞的杀伤率明显高于pH6.5时。CIK条件培养液作用下,pH7.4时HepG2细胞的凋亡坏死比例明显高于pH6.5。结论酸性环境明显抑制了CIK细胞对肝癌细胞HepG2的杀伤活性。 Objective To investigate the effect of acid environment on the cytotoxicity of cytokine-induced killer(CIK) cells against hepatocellular carcinoma cells HepG2. Methods CIK cells were induced from peripheral blood mononuclear cells with IFN-γ, IL-2 and CD3 m Ab. HepG2 cells and luciferase marked HepG2 cells(HepG2-luc) were co-cultured with CIK cells at different effect/target ratios, and the medium were adjusted at pH6.5 and pH7.4 respectively. The luciferase intensity of HepG2-luc was detected with IVIS Spectrum System, and the cytotoxicity was calculated according to luciferase intensity and MTT assay. HepG2 cells were cultured with the medium including 0, 50% and 100% CIK at pH6.5 and pH7.4 respectively. The apoptosis and necrotic cells percentage were detected by flow cytometry. Results The cytotoxicity of CIK cells at pH7.4 were significantly higher than that at pH6.5. Also, in CIK condition medium, the percentage of apoptosis and necrotic HepG2 cells at pH7.4 condition was significantly higher than that at pH6.5. Conclusion Acid environment markedly inhibits the cytotoxicity of CIK cells against hepatocellular carcinoma cells HepG2.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2016年第5期331-334,共4页 Cancer Research on Prevention and Treatment
基金 国家科技部重大专项子课题(2013ZX10001004-002-005)
关键词 CIK 酸性环境 HEPG2 杀伤活性 Cytokine-induced killer(CIK) Acid environment HepG2 Cytotoxicity
  • 相关文献

参考文献1

二级参考文献28

  • 1Golovina TN, Vonderheide RH. Regulatory T cells: over- coming suppression of T-cell immunity. Cancer J 2010; 16: 342-347.
  • 2Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E, Knolle PA, Thomas RK, von Bergwelt-Baildon M, DebeyS, Hallek M, Schultze JL. Reduced percentages and suppres- sive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106:2018-2025.
  • 3Kerbel RS, Kamen BA. The anti-angiogenic basis of metro- nomic chemotherapy. Nat Rev Cancer 2004; 4:423-436.
  • 4Bronte V, Mocellin S. Suppressive influences in the immune response to cancer. J Immunother 2009; 32:1-11.
  • 5Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavrou- kakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP,Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA. Adoptive cell transfer therapy following non-myeloablative but lymphodepletingchemotherapy for the treatment of patients with refractory metastatic melanoma. ] Clin Oncol 2005; 23:2346-2357.
  • 6Wang LX, Shu S, Plautz GE. Host lymphodepletion aug- ments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells. Cancer Res 2005; 65:9547-9554.
  • 7Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Menard S, Tagliabue E, Balsari A. FOXP3 expression and overall survival in breast cancer. J Clin Oncol 2009; 27: 1746-1752.
  • 8Colombo MP, Piconese S. Regulatory-T-cell inhibition ver- sus depletion: the right choice in cancer imrnunotherapy.Nat Rev Cancer 2007; 7:88-887.
  • 9Dirkx AE, oude Egbrink MG, Castermans K, van der Schaft DW, Thijssen VL, Dings RP, Kwee L, Mayo KH, Wagstaff J, Bouma-ter Steege JC, Griffioen AW. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tu- mors. FASEB J 2006; 20:621-630.
  • 10Tan GH, Tian L, Wei YQ, Zhao X, Li J, Wu Y, Wen YJ, Yi T, Ding ZY, Kan B, Mao YQ, Deng HX, Li HL, Zou CH, Fu CH. Combination of low-dose cisplatin and recombinant xeno- geneic endoglin as a vaccine induces synergistic antitumor activities. Int J Cancer 2004; 112:701-706.

共引文献17

同被引文献9

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部